

*Variant: NM\_001130987.2(DYSF):c.2125C>T (p.Gln709Ter)*

Version: 1.0

CA49797983 [↗](#)

963357 (ClinVar) [↗](#)

**Gene:** [DYSF \(HGNC:8291\)](#)

**Condition:** [autosomal recessive limb-girdle muscular dystrophy \(MONDO:0015152\)](#)

**Inheritance Mode:** [Autosomal recessive inheritance](#)

**UUID:** 13697906-1bb2-49d3-80e1-d5e51b59803c

**Approved on:** 2025-10-29

**Published on:** 2025-11-11

### *HGVS expressions*

**NM\_001130987.2:c.2125C>T**

NM\_001130987.2(DYSF):c.2125C>T (p.Gln709Ter)

NC\_000002.12:g.71555980C>T

CM000664.2:g.71555980C>T

NC\_000002.11:g.71783110C>T

CM000664.1:g.71783110C>T

NC\_000002.10:g.71636618C>T

NG\_008694.1:g.107358C>T

ENST00000258104.8:c.2071C>T

ENST00000410020.8:c.2125C>T

ENST00000258104.7:c.2071C>T

ENST00000394120.6:c.2074C>T

ENST00000409366.5:c.2074C>T

ENST00000409582.7:c.2122C>T

ENST00000409651.5:c.2167C>T

ENST00000409744.5:c.2032C>T

ENST00000409762.5:c.2122C>T

ENST00000410020.7:c.2125C>T

ENST00000410041.1:c.2125C>T

ENST00000413539.6:c.2164C>T

ENST00000429174.6:c.2071C>T

NM\_001130455.1:c.2074C>T

NM\_001130976.1:c.2029C>T

NM\_001130977.1:c.2029C>T

NM\_001130978.1:c.2071C>T

NM\_001130979.1:c.2164C>T

NM\_001130980.1:c.2122C>T

NM\_001130981.1:c.2122C>T

NM\_001130982.1:c.2167C>T

NM\_001130983.1:c.2074C>T

NM\_001130984.1:c.2032C>T

NM\_001130985.1:c.2125C>T

NM\_001130986.1:c.2032C>T

NM\_001130987.1:c.2125C>T

NM\_003494.3:c.2071C>T

NM\_001130455.2:c.2074C>T

NM\_001130976.2:c.2029C>T

NM\_001130977.2:c.2029C>T  
NM\_001130978.2:c.2071C>T  
NM\_001130979.2:c.2164C>T  
NM\_001130980.2:c.2122C>T  
NM\_001130981.2:c.2122C>T  
NM\_001130982.2:c.2167C>T  
NM\_001130983.2:c.2074C>T  
NM\_001130984.2:c.2032C>T  
NM\_001130985.2:c.2125C>T  
NM\_001130986.2:c.2032C>T  
NM\_003494.4:c.2071C>T

**Pathogenic**

Met criteria codes **4**

PP4\_Strong PVS1 PM3  
PM2\_Supporting

Evidence Links **0**

Expert Panel

[Limb Girdle Muscular Dystrophy VCEP](#)

Criteria Specification Information

- [Criteria Specification: ClinGen Limb Girdle Muscular Dystrophy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for DYSF Version 2.0.0](#)
- [Criteria Specification Approval History](#)
- [Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

### ***Limb Girdle Muscular Dystrophy VCEP***

The NM\_003494.4: c.2071C>T p.(Gln691Ter) variant in DYSF, which is also known as NM\_001130987.2: c.2125C>T p.(Gln709Ter), is a nonsense variant predicted to cause a premature stop codon in biologically relevant exon 22/55, leading to nonsense mediated decay in a gene in which loss of function is an established disease mechanism (PVS1). This variant has been identified in two individuals with LGMD (PMID: 33610434, 36983702), including confirmed in trans in one individual with a pathogenic variant (NM\_003494.4: c.3113G>A p.(Arg1038Gln), 1 pt, PMID: 36983702) (PM3). Both individuals had absent dysferlin protein expression, which is highly specific for DYSF-related LGMD, and one individual also displayed progressive muscle weakness (PP4\_Strong). The upper bound of the 95% confidence interval of the Grpmax variant allele frequency in gnomAD v4.1.0 is 0.000014703 (10/1153648 European (non-Finnish) alleles), which is less than the ClinGen LGMD VCEP threshold ( $\leq 0.0001$ ) (PM2\_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb-girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 2.0.0; 10/29/2025): PVS1, PP4\_Strong, PM3, PM2\_Supporting.

Met criteria codes

**PP4\_Strong**



Both individuals had absent dysferlin protein expression, which is highly specific for DYSF-related LGMD, and one individual also displayed progressive muscle weakness (PP4\_Strong).

**PVS1**



The NM\_003494.4: c.2071C>T p.(Gln691Ter) variant in DYSF, which is also known as NM\_001130987.2: c.2125C>T p.(Gln709Ter), is a nonsense variant predicted to cause a premature stop codon in biologically relevant exon 22/55, leading to nonsense mediated decay in a gene in which loss of function is an established disease mechanism (PVS1).

**PM3**



This variant has been identified in two individuals with LGMD (PMID: 33610434, 36983702), including confirmed in trans in one individual with a pathogenic variant (NM\_003494.4: c.3113G>A p.(Arg1038Gln), 1 pt, PMID: 36983702) (PM3).

**PM2\_Supporting**



The upper bound of the 95% confidence interval of the Grpmax variant allele frequency in gnomAD v4.1.0 is 0.000014703 (10/1153648 European (non-Finnish) alleles), which is less than the ClinGen LGMD VCEP threshold ( $\leq 0.0001$ ) (PM2\_Supporting).

#### Curation History [↗](#)

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.